Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

14-day bismuth quadruple regimen containing cefuroxime and tetracycline

14-day bismuth quadruple regimen containing cefuroxime and tetracycline:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Tetracycline 500mg tid,14 days.Evaluating the efficacy and safety of 14-Day bismuth quadruple therapy containing cefuroxime and tetracycline for Helicobacter pylori eradication.

DRUG

14-day bismuth quadruple regimen containing cefuroxime and levofloxacin

14-day bismuth quadruple regimen containing cefuroxime and levofloxacin:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Levofloxacin 500mg qd,14 days.

Trial Locations (1)

250012

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER

NCT06351891 - Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin | Biotech Hunter | Biotech Hunter